316 related articles for article (PubMed ID: 33434043)
1. Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
Khaldoyanidi S; Nagorsen D; Stein A; Ossenkoppele G; Subklewe M
J Clin Oncol; 2021 Feb; 39(5):419-432. PubMed ID: 33434043
[No Abstract] [Full Text] [Related]
2. Natural killer cell immune escape in acute myeloid leukemia.
Lion E; Willemen Y; Berneman ZN; Van Tendeloo VF; Smits EL
Leukemia; 2012 Sep; 26(9):2019-26. PubMed ID: 22446501
[TBL] [Abstract][Full Text] [Related]
3. Immune escape and immunotherapy of acute myeloid leukemia.
Vago L; Gojo I
J Clin Invest; 2020 Apr; 130(4):1552-1564. PubMed ID: 32235097
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
6. [Immune stimulation as oncologic therapy, especially in acute leukemia].
Olsson L
Ugeskr Laeger; 1977 Apr; 139(15):876-9. PubMed ID: 265645
[No Abstract] [Full Text] [Related]
7. The role of various interleukins in acute myeloid leukemia.
Kaser EC; Zhao L; D'mello KP; Zhu Z; Xiao H; Wakefield MR; Bai Q; Fang Y
Med Oncol; 2021 Apr; 38(5):55. PubMed ID: 33835290
[TBL] [Abstract][Full Text] [Related]
8. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.
Isidori A; Salvestrini V; Ciciarello M; Loscocco F; Visani G; Parisi S; Lecciso M; Ocadlikova D; Rossi L; Gabucci E; Clissa C; Curti A
Expert Rev Hematol; 2014 Dec; 7(6):807-18. PubMed ID: 25227702
[TBL] [Abstract][Full Text] [Related]
9. Immune therapy of AML.
Molldrem J
Cytotherapy; 2002; 4(5):437-8. PubMed ID: 12473216
[No Abstract] [Full Text] [Related]
10. Editorial: Targets for Immunotherapy in Acute Leukemia.
Hourigan CS
Curr Drug Targets; 2017; 18(3):256. PubMed ID: 28264642
[No Abstract] [Full Text] [Related]
11. Active immunotherapy trials on acute lymphoid leukemia lymphosarcoma and acute myeloid leukemia.
Mathe G; Schwarzenberg L; Delgado M; De Vassal F
Eur J Cancer (1965); 1977; 13(4-5):445-55. PubMed ID: 326558
[No Abstract] [Full Text] [Related]
12. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
13. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy prospects for acute myeloid leukaemia.
Barrett AJ; Le Blanc K
Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Profile of Immunotherapy Approaches in the Treatment of AML.
Daver N
Oncology (Williston Park); 2019 Jan; 33(1):28-32. PubMed ID: 30731016
[No Abstract] [Full Text] [Related]
16. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
17. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
18. Current strategies in immunotherapy for acute myeloid leukemia.
Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
Muntasell A; López-Botet M
Clin Cancer Res; 2016 Apr; 22(8):1831-3. PubMed ID: 26903071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
